Intuitive Surgical (ISRG) Stock Forecast & Price Target

$366.70 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Compare

Intuitive Surgical - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 31 Analyst Ratings

Sell
1

Hold
8

Buy
22

Based on 31 Wall Street analysts who have issued ratings for Intuitive Surgical in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 31 analysts, 1 has given a sell rating, 8 have given a hold rating, and 22 have given a buy rating for ISRG.

Consensus Price Target

$508.68
38.72% Upside

According to the 31 analysts' twelve-month price targets for Intuitive Surgical, the average price target is $508.68. The highest price target for ISRG is $685.00, while the lowest price target for ISRG is $357.44. The average price target represents a forecasted upside of 38.72% from the current price of $366.70.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for ISRG and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Intuitive Surgical and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ISRG Analyst Ratings Over Time

Type	Current Forecast 9/8/25 to 9/8/26	1 Month Ago 8/9/25 to 8/9/26	3 Months Ago 6/10/25 to 6/10/26	1 Year Ago 9/8/24 to 9/8/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	22 Buy rating(s)	20 Buy rating(s)	19 Buy rating(s)	13 Buy rating(s)
Hold	8 Hold rating(s)	8 Hold rating(s)	7 Hold rating(s)	6 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$508.68	$509.02	$573.63	$595.95
Forecasted Upside	38.72% Upside	34.37% Upside	39.22% Upside	26.80% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

ISRG Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ISRG Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Intuitive Surgical Stock vs. The Competition

Type	Intuitive Surgical	Healthcare Companies	Broader Market
Consensus Rating Score	2.68	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	38.72% Upside	928.67% Upside	14.03% Upside
News Sentiment Rating	Positive News See Recent ISRG News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/21/2026	Piper Sandler 2 of 5 stars	Adam Maeder 2 of 5 stars	Reiterated Rating	Overweight
8/14/2026	Weiss Ratings 5 of 5 stars		Reiterated Rating	Hold (C)
8/12/2026	Sanford C. Bernstein 3 of 5 stars	Lee Hambright Not Rated	Reiterated Rating	Outperform
8/12/2026	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight
8/12/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Suraj Kalia Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$500.00	+24.62%
7/30/2026	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Helen Fang Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$391.00	+10.73%
7/28/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Priya Sachdeva Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy ➝ Neutral	$500.00	+36.64%
7/28/2026	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Outperform
7/28/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mathew Blackman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/20/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vik Chopra Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform
SpaceX pays a 10X launch penalty (Ad) SpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One under $5 company's High Altitude Head Start technology could bring that down to $20,000 per launch, or $2 million across 100 missions - a 10X cost advantage. It is already flying with paying customers, but shares may not stay this cheap once Wall Street notices. Click here to reveal the ticker before Wall Street catches on
7/17/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jayson Bedford Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$577.00 ➝ $483.00	+34.54%
7/17/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$654.00 ➝ $487.00	+21.04%
7/17/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$550.00 ➝ $450.00	+27.00%
7/17/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$670.00 ➝ $550.00	+36.70%
7/17/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joanne Wuensch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$590.00 ➝ $500.00	+24.28%
7/17/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ryan Zimmerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$512.00 ➝ $469.00	+16.57%
7/17/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Rescott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$525.00 ➝ $500.00	+24.28%
7/17/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Kratky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$573.00 ➝ $454.00	+12.84%
7/16/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Newitter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$580.00 ➝ $510.00	+27.78%
7/15/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Neutral	$525.00 ➝ $500.00	+29.84%
7/13/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$650.00 ➝ $600.00	+46.77%
7/6/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$430.00	+1.32%
6/12/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target		$520.00 ➝ $515.00	+26.78%
6/2/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Sell	$440.00 ➝ $366.00	-8.82%
5/27/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Roman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$558.00	+30.63%
4/23/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Overweight	$712.00 ➝ $651.00	+34.61%
4/22/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Hold	$560.00 ➝ $515.00	+7.00%
3/30/2026	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
2/4/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$630.00 ➝ $560.00	+17.03%
10/24/2025	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$510.00 ➝ $550.00	+0.28%
10/23/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$610.00 ➝ $615.00	+16.69%
7/23/2025	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold
1/27/2025	CICC Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Neutral	$550.00	-4.17%
1/27/2025	Bernstein Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Overweight	$655.00 ➝ $700.00	+22.16%
12/2/2024	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight	$522.00 ➝ $650.00	+19.93%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:20 AM ET.

Should I Buy Intuitive Surgical Stock? ISRG Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, September 6, 2026. Please send any questions or comments about these Intuitive Surgical pros and cons to contact@marketbeat.com.

Intuitive Surgical
Bull Case

Here are some ways that investors could benefit from investing in Intuitive Surgical, Inc.:

Intuitive Surgical, Inc. recently reported strong financial results for the quarter ended July 16, 2026, with earnings per share of $2.80, which exceeded the consensus estimate of $2.48 by $0.32, demonstrating the company's ability to outperform market expectations and drive shareholder value through robust profitability.
The company's revenue for the most recent quarter reached $2.89 billion, surpassing analyst estimates of $2.83 billion and marking an 18.4% year-over-year increase, which indicates sustained demand for its robotic-assisted surgical systems and related services in the healthcare sector.
Intuitive Surgical, Inc. maintains a high return on equity of 16.91% and a net margin of 28.45%, reflecting efficient capital management and strong operational profitability that can support long-term wealth accumulation for investors in the medical equipment industry.
With the current stock price at $366.70, the shares are trading significantly below the consensus price target of $508.68, suggesting a potential upside of approximately 38.7% for investors who believe the market has overreacted to recent volatility or temporary headwinds.
Institutional interest in the stock remains strong, as evidenced by the Saudi Central Bank increasing its stake by 90.0% in the second quarter and Munich Reinsurance Co Stock Corp in Munich growing its holdings by 48.0%, indicating that major global financial institutions are confident in the company's long-term stability and growth prospects.

Intuitive Surgical
Bear Case

Investors should be bearish about investing in Intuitive Surgical, Inc. for these reasons:

The stock is currently trading at $366.70, which is well below its 52-week high of $603.88 and its 200-day simple moving average of $428.60, indicating a significant downward trend and potential continued pressure on the share price as it remains in a correction phase.
Intuitive Surgical, Inc. faces increasing competition in the surgical robotics space, with well-heeled competitors entering the market, which could erode the company's market share and pricing power, posing a risk to its dominant position in the industry.
Recent insider activity shows a pattern of selling, with executives such as Gary S. Guthart, Amy L. Ladd, and Gary Loeb selling shares in August 2026, which may signal a lack of confidence in the near-term stock performance or a desire to diversify personal holdings away from the company.
The company's growth rate has cooled from its post-pandemic highs, with revenue growth slowing to 18.4% in the most recent quarter compared to higher rates in previous periods, suggesting that the rapid expansion phase may be maturing and future growth could be more modest.
Intuitive Surgical, Inc. has a high P/E ratio of 42.00, which is expensive relative to many other healthcare companies, meaning investors are paying a premium for its earnings that may not be justified if growth slows or if the company faces increased competition and regulatory pressures.

ISRG Forecast - Frequently Asked Questions

According to the research reports of 31 Wall Street equities research analysts, the average twelve-month stock price forecast for Intuitive Surgical is $508.68, with a high forecast of $685.00 and a low forecast of $357.44.

31 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intuitive Surgical in the last twelve months. There is currently 1 sell rating, 8 hold ratings and 22 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ISRG shares.

According to analysts, Intuitive Surgical's stock has a predicted upside of 38.72% based on their 12-month stock forecasts.

Over the previous 90 days, Intuitive Surgical's stock had 4 upgrades and 2 downgrades by analysts.

Intuitive Surgical has been rated by research analysts at Bank of America, BMO Capital Markets, BNP Paribas Exane, BTIG Research, Citigroup, Evercore, HSBC, JPMorgan Chase & Co., KeyCorp, Leerink Partners, Mizuho, Oppenheimer, Piper Sandler, Raymond James Financial, Robert W. Baird, Royal Bank Of Canada, Sanford C. Bernstein, Stifel Nicolaus, TD Cowen, Truist Financial, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Intuitive Surgical more than other "healthcare" companies. The consensus rating for Intuitive Surgical is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how ISRG compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Intuitive Surgical Recommendations

MarketBeat monitors more than a dozen sources for Intuitive Surgical analyst ratings, with the most recent rating issued on 8/21/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intuitive Surgical (ISRG) Stock Forecast & Price Target

Intuitive Surgical - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ISRG Analyst Ratings Over Time

ISRG Analyst Recommendations By Month

ISRG Price Targets by Month

Intuitive Surgical Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Intuitive Surgical Stock? ISRG Pros and Cons Explained

Intuitive Surgical
Bull Case

Intuitive Surgical
Bear Case

ISRG Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Intuitive Surgical Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Intuitive Surgical (ISRG) Stock Forecast & Price Target

Intuitive Surgical - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ISRG Analyst Ratings Over Time

ISRG Analyst Recommendations By Month

ISRG Price Targets by Month

Intuitive Surgical Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Intuitive Surgical Stock? ISRG Pros and Cons Explained

Intuitive Surgical Bull Case

Intuitive Surgical Bear Case

ISRG Forecast - Frequently Asked Questions

What is Intuitive Surgical's forecast for 2026?

Should I buy or sell Intuitive Surgical stock right now?

Does Intuitive Surgical's stock price have much upside?

Has Intuitive Surgical been upgraded or downgraded by Wall Street analysts recently?

What analysts cover Intuitive Surgical?

Do Wall Street analysts like Intuitive Surgical more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Intuitive Surgical Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Intuitive Surgical
Bull Case

Intuitive Surgical
Bear Case